Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 9/20 | 0.48 |
| ▸ | HTR1A | P08908 | 8/20 | 0.46 |
| ▸ | HTR1D | P28221 | 8/20 | 0.46 |
| ▸ | HTR1B | P28222 | 8/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180465 | 0.88 | HTR1A (0.59) | HTR1AHTR1DHTR1BHRH4 | |
| SCHEMBL6179721 | 0.81 | HTR6 (0.39) | HTR6 | |
| SCHEMBL6179690 | 0.81 | HTR1A (0.51) | HTR1AHTR1DHTR1B | |
| SCHEMBL6180139 | 0.80 | HTR1A (0.39) | HTR1AHTR1DHTR1B | |
| SCHEMBL6180135 | 0.79 | HTR1A (0.49) | HTR6HTR1AHTR1DHTR1B | |
| SCHEMBL6179435 | 0.74 | HTR1A (0.39) | HTR6HTR1AHTR1DHTR1B | |
| SCHEMBL6179304 | 0.73 | HTR1A (0.64) | HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL6180948 | 0.72 | HTR1A (0.60) | HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL6179444 | 0.71 | PTGDR2 (0.37) | HTR1AHTR1DHTR1B | |
| SCHEMBL3681817 | 0.71 | HTR2C (0.59) | HTR2CHTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1228043-A1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032626-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | HTR2C 5/4885HTR6 16/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.